HER2-Positive Metastatic Breast Cancer: The Treatment Shift Reshaping the Market
A Decade of Reinvention There was a time when a HER2-positive breast cancer diagnosis carried a particularly difficult outlook. The biology was aggressive, treatment options were limited, and metasta ...
ESMO 2026 Preview: What the Abstracts Reveal Before the Data Drops
Every major oncology congress has its headline moments: a trial that changes practice, a therapy that exceeds expectations, or a new mechanism that suddenly becomes the industry's next big focus.But E ...